Apple stock is for conservative, dividend growth investors, as it has all the attributes we'd want in a dividend growth stock ...

Straumann is in fine financial health. The firm has a healthy balance sheet and it has been averse to taking on any significant debt. It has held a debt/EBITDA below 1, on average, over the past 10 ...

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

Boliden AB (BLIDF) reports a robust SEK2.6 billion operating profit, while navigating negative free cash flow and strategic acquisitions.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s ...

This is an important study utilizing innovative CRISPR based approaches demonstrating the role of the KLF family of transcription factors in the post natal maturation of cortical projection neurons.

Challenges for all allogeneic cell therapy developers include achieving the same efficacy and durability as the first generation of cell therapies, which are made by engineering a patient’s own ...

HOUSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.